429P Givinostat in Duchenne muscular dystrophy: natural history comparison applying propensity score matching
C. McDonald, Stefano Cazzaniga(University of Verona), Mariacristina Scoto(University College London), K. Vandenborne, M. Guglieri, Valeria Sansone(University of Milan), N. Coceani(Italfarmaco (Italy)), P. Bettica(Italfarmaco (Italy)), H. Phan(Rare Disease Therapeutics (United States)), Tracey Willis(Robert Jones and Agnes Hunt Orthopaedic Hospital)
Cited by 1
Related Papers
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
|Neuromuscular Disorders|2019|636
Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial
|Nucleic Acid Therapeutics|2021|128
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Neurology|2024|128